Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

Journal of Clinical Investigation

Volumn 115, Issue 6, 2005, Pages 1616-1626

  Gattinoni, Luca ^a   Klebanoff, Christopher A ^a,b   Palmer, Douglas C ^a   Wrzesinski, Claudia ^a   Kerstann, Keith ^a   Yu, Zhiya ^a   Finkelstein, Steven E ^a   Theoret, Marc R ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HOMEOSTASIS; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL AGING; CELL PROLIFERATION; CELL SURVIVAL; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; RECEPTORS, LYMPHOCYTE HOMING; T-LYMPHOCYTE SUBSETS;

EID: 20444499355     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24480     Document Type: Article

References (53)

1. Rosenberg, S.A., Yang J.C., and Restifo, N.P. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-915.
2. Dudley, M.E., and Rosenberg, S.A. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer. 3:666-675.
3. Childs, R.W., and Barrett, J. 2004. Nonmyeloablative allogeneic immunotherapy for solid tumors. Annu. Rev. Med. 55:459-475.
4. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
5. Rosenberg, S.A., and Dudley, M.E. 2004. Cancer regression in paciencs with mecastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 101(Suppl. 2):14639-14645.
6. Sallusto, F., Geginat, J., and Lanzavecchia, A. 2004. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol 22:745-763.
7. Masopust, D., Kaech, S.M., Wherry, E.J., and Ahmed, R. 2004. The role of programming in memory T-cell development. Curr: Opin. Immunol. 16:217-225.
8. Appay, V., and Rowland-Jones, S.L. 2004, Lessons from the study of T-cell differentiation in persistent human virus infection. Semin. Immunol. 16:205-212.
9. Maus, M.V., et al. 2004. Extensive replicative capacity of human central memory T cells. J. Immunol. 172:6675-6683.
10. Yee, C., et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T celts. Proc. Natl Acad. Sci. U. S. A. 99:16168-16173.
11. Dudley, M.E., et al. 2001. Adoptive transfer of cloned melanoma-reactive T lymphocyces for the treatment of patients with metastatic melanoma. J. Immunother. 24:363-373.
12. Dudley, M.E., et al. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:243-251.
13. Overwijk, W.W., et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198:569-580.
14. Gold, J.S., et al. 2003. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol. 170:5188-5194.
15. Turk, M.J., Guevara-Patino, J.A., Rizzuto, G.A., Engelhorn, M.E., and Houghton, A.N. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200:771-782.
16. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173:7209-7216.
17. + T cell function by the transcription factor Eomesodermin. Science. 302:1041-1043.
18. Danial, N.N., and Korsmeyer, S.J., 2004. Cell death: critical control points. Cell. 116:205-219.
19. Hildeman, D.A., Mitchell, T., Kappler, J., and Marrack, P. 2003. T cell apoptosis and reactive oxygen species. J Clin. Invest. 111:575-581. doi:10.1172/JCI200318007.
20. Degli, E.M., et al. 2003. Post-translational modification of Bid has differencial effects on its susceptibility to cleavage by caspase 8 or caspase 3. J. Biol. Chem. 278:15749-15757.
21. Voehringer, D., et al. 2001, Viral infections induce abundant numbers of senescent CD8 T cells. J. Immunol. 167:4838-4843.
22. Voehringer, D., Koschella, M., and Pircher, H. 2002. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood. 100:3698-3702.
23. Bertram, M.J., et al. 1999. Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol. Cell. Biol 19:1479-1485.
24. Lanzavecchia, A., and Sallusto, F. 2002. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2:982-987.
25. Von Andrian, U.H., and Mempel, T.R. 2003. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 3:867-878.
26. Weninger, W., Crowley, M.A., Manjunath, N., and Von Andrian, U.H. 2001. Migratory properties of naive, effector, and memory CD8(+) T cells. J. Exp. Med. 194:953-966.
27. Speiser, D.E., et al. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
28. Powell, D.J., Jr., Dudley, M.E., Robbins, P.P., and Rosenberg, S.A. 2005. Transition of late-stage effector T cells to CD27+ CD28- tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 105:241-250.
29. Klebanoff, C.A., et al. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci U. S. A. 101:1969-1974.
30. Manjunath, N., et al. 2001. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J. Clin. Invest. 108:871-878. doi:10.1172/JCI200113296.
31. Wherry, E.J., et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol 4:225-234.
32. Kagamu, H., Touhalisky J.E., Plautz, G.E., Krauss, J.C., and Shu, S. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338-4342.
33. Hendriks, J., et al. 2000. CD27 is required for generation and tong-term maintenance of T cell immunity. Nat. Immunol. 1:433-440.
34. Hendriks, J., Xiao, Y., and Borst, J. 2003. CD27 promotes survival of activated T cells and complements CD28 in generarion and establishment of the effector T cell pool. J. Exp. Med. 198:1369-1380.
35. Arens, R., et al. 2004. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J. Exp. Med. 199:1595-1605.
36. Rowley, T.F., and Al Shamkhani, A. 2004. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J. Immunol. 172:6039-6046.
37. Liu, K., and Rosenberg, S.A. 2001. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167:6356-6365.
38. Antony, P.A., et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174:2591-2601.
39. Schluns, K.S., Kieper, W.C., Jameson, S.C., and Lefrancois, L. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1:426-432.
40. Goldrath, A.W., et al. 2002. Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8+ T cells. J. Exp. Med. 195:1515-1522.
41. Kaech, S. M., et al. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:1191-1198.
42. Huster, K.M., et al. 2004. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc. Natl. Acad. Sci. U. S. A. 11:5610-5615.
43. Tan J.T., et al. 2002. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195:1523-1532.
44. Judge, A.D., Zhang, X., Fujii, H., Surh, C.D., and Sprent, J. 2002. Interleukin 15 controls both proliferation and survival of a subset of memory-phenoctype CD8(+) T cells. J. Exp. Med. 196:935-946.
45. Tuma, R.A., and Pamer, E.G. 2002. Homeostasis of naive, effector and memory CD8 T cells. Curr. Opin. Immunol. 14:348-353.
46. Dubois, S., Mariner, J., Waldmann, T.A., and Tagaya, Y. 2002. IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity. 17:537-547.
47. Schluns, K.S., Klonowski, K.D., and Lefrancois., L. 2004. Transregulation of memory CD8 T-cell proliferation by IL-15R{alpha}-+bone marrow-derived cells. Blood. 103:988-994.
48. Robbins, P.F., et al. 2004. Cutting edge: persistence of transferred lymphocyte clonocypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173:7125-7130.
49. Papagno, L., et al. 2004. Immune activation and CD8(+) T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2:E20. doi:10.1371/journal.pbio.0020020.
50. Heintel, T., et al. 2002. The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS. 16:1497-1501.
51. Migueles, S.A., et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-1068.
52. Walter, E.A., et al. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
53. Overwijk, W.W., et al. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.